IL13 and chronic obstructive pulmonary disease: Biologics targeting IL-4Rα, such as dupilumab, inhibit IL-13 signalling at its receptor, suppressing pathological Ca2+-mediated effects on both ASM and epithelium, providing a mechanism-based approach for selected COPD phenotypes with Th2-driven inflammation [1,171,172].